Opendata, web and dolomites

FAIR SIGNED

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FAIR project word cloud

Explore the words cloud of the FAIR project. It provides you a very rough idea of what is the project "FAIR" about.

markers    cohorts    plan    gain    optimal    nebuliser    public    assessing    device    health    industrial    subpopulation    adjunct    therapy    trial    amr    pharmacodynamics    antibiotics    site    simulation    protection    innate    innovation    faced    mechanisms    resistant    acceptability    morbidity    models    report    relative    antibiotic    nebulization    infection    enrichment    care    effectiveness    immune    leverages    trials    outcomes    emergence    capacity    strengthens    benefit    antimicrobial    relevance    preclinical    overcome    worldwide    predict    outcome    course    validation    economic    enhances    nebulized    fair    defences    airway    epithelial    safety    mortality    drug    infections    straightforward    alone    flagellin    host    therapeutic    recommendations    model    rapid    treatments    modalities    stakeholders    avenues    pharmacokinetics    pipeline    constitute    bacterial    pneumonia    clinical    biology    aerosol    curative    analyze    patients    treatment    action    standard    resistance    stratification    immunomodulatory   

Project "FAIR" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 10˙162˙903 €
 EC max contribution 10˙162˙903 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 3˙701˙150.00
2    STATENS SERUM INSTITUT DK (KOBENHAVN S) participant 2˙057˙770.00
3    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 1˙200˙170.00
4    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS FR (TOURS CEDEX 9) participant 644˙940.00
5    FREIE UNIVERSITAET BERLIN DE (BERLIN) participant 567˙750.00
6    EPITHELIX SARL CH (PLAN LES OUATES) participant 496˙000.00
7    UNIVERSITE DE LILLE FR (LILLE) participant 380˙687.00
8    UNIVERSITY OF SOUTHAMPTON UK (SOUTHAMPTON) participant 367˙186.00
9    INSERM - TRANSFERT SA FR (PARIS) participant 300˙750.00
10    EUROPEAN RESPIRATORY SOCIETY CH (LAUSANNE) participant 235˙812.00
11    AEROGEN LTD IE (GALWAY) participant 210˙687.00

Map

 Project objective

Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure. The FAIR consortium aims at assessing an adjunct to antibiotic therapy as an emerging concept of overcome AMR in pneumonia. The project leverages (i) a unique immunomodulatory flagellin that enhances airway epithelial innate immune defences and increases the therapeutic outcome relative to antibiotic alone, and (ii) airway-specific aerosol delivery by nebulization.

FAIR’s objectives are to: • develop nebulization modalities for optimal airway targeting and rapid action at the infection site • demonstrate that nebulized flagellin strengthens the response to antibiotics in relevant preclinical models of antibiotic-resistant pneumonia • identify host immune factors required for the gain of protection with systems biology • implement pharmacokinetics/pharmacodynamics model-based design and simulation for clinical validation • assess nebulized flagellin’s safety in a Phase I clinical trial. • analyze the acceptability and economic relevance of the therapy • identify stratification markers that predict the course of pneumonia and treatment in antibiotic-treated cohorts.

Expected outcomes include the enrichment of the pipeline of novel treatments against pneumonia, reinforcement of EU capacity to control AMR and infections, the Phase I safety report on nebulized flagellin, recommendations for future trials, and acceptability by the stakeholders and cost-effectiveness for public health. FAIR will develop new avenues of research on mechanisms of action of the adjunct flagellin, and will define (for future trials) the subpopulation of patients that might benefit most from this treatment. Our industrial partnerships and exploitation plan will enable straightforward development of drug and nebuliser device, and bring innovation to the patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FAIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More